Viral-induced Adaptation of Neutrophil Response in ARDS
R01 HL090991
PI: Jerry A. Nick
Current Award Period: 7/24/09-5/31/10
Total Award Period: 7/24/07-5/31/11
Current Award Budget: $363,911
Total Award Budget: $1,455,644
Specific Aims:
- Prospectively test in ARDS patients the effect of neutrophil Interferon Stimulated Gene (ISG) upregulation on clinical parameters of disease severity and outcome.
- Prospectively test in neutrophils isolated from ARDS patients the effect of ISG upregulation on cellular response to pro-inflammatory stimuli and live bacteria.
- Prospectively test in ARDS patients the predictive value of ISG upregulation in whole blood as a biomarker of viral infection and a more severe clinical course.
ARRA Supplement to Viral-induced Adaptation of Neutrophil Response in ARDS
R01 HL090991-03S2
PI: Jerry A. Nick
Current Award Period: 7/01/09-6/30/10
Total Award Period: 7/01/09-6/30/11
Current Award Budget: $141,602
Total Award Budget: $283,204
Specific Aims:
- Define a global gene expression profile in neutrophils from ARDS patients with high and low ISG expression.
- Test the ability of a directed gene expression profile of ISG upregulation to predict disease severity and outcome in ARDS.
ARRA Student Supplement to Viral-induced Adaptation of Neutrophil Response in ARDS
R01 HL090991-03S1
PI: Jerry A. Nick
Total Award Period: 7/01/09-6/30/11
Total Award Budget: $14,102
Specific Aim: Provide summer research experience for students and science educators.
Targeted Prevention or Treatment of Bacterial Biofilm Infections of Severe Burns and Wounds
Congressionally Directed Medical Research
Programs DR080371
PI: Jerry A. Nick
Current Award Period: 9/23/09-4/22/11
Total Period: 9/23/09-4/22/11
Current Award Budget: $233,618
Total Budget: $233,618
Specific Aims:
- Test the capacity of N2 peptide, with and without azithromycin, to prevent post-burn P. aeruginosa wound infection.
- Test the capacity of N2 peptide with and without azithromycin to treat established P. aeruginosa wound infection, or to augment standard antibiotic treatment.
Prevention and Disruption of Pseudomonas aeruginosa biofilms
NJC CF Award
Max and Yetta Karasik Foundation for CF Research
PI: Jerry A. Nick
Current Award Period: 10/1/09-9/30/10
Total Award Period: 10/1/02-9/30/10
Current Award Budget: $42,375
Total Award Budget: $246,618
Specific Aims:
- Develop a method to directly visualize the creation of P. aeruginosa biofilms via incorporation of polymers of F-actin and DNA.
- Test the capacity of treatments that depolymerize F-actin and DNA to disrupt P. aeruginosa biofilm from CF strains early and late in infection.
- Test the capacity of disruption of P. aeruginosa biofilm to facilitate antibiotic killing of the infection.
Colorado Bioscience Discovery Evaluation Grant Program
A Novel Compound For Pseudomonas Biofilm Disruption
PI: Jerry A. Nick
Award Period: 3/1/011-6/1/12
Current Budget: $79,800
Specific Aims:
- Synthesis of unique candidate molecules,
- Test in vitro the capacity of candidate molecules to disrupt medically relevant PA biofilms,
- Test in vivo the efficacy of candidate molecules to enhance antibiotic therapy of PA infection in a murine thermal injury model.
Cystic Fibrosis Foundation Care Center Award
CF Foundation
PI: Jerry A. Nick
Current Award Period: 7/1/10-6/30/11
Total Award Period: 7/1/05-6/30/11
Current Award Budget: $84,000
Total Award Budget: $372,500
Specific Aim: Registry of CF patients served by the Adult CF Program
Cystic Fibrosis Foundation Translational Therapeutic Development Center Award
CF Foundation
Co-Investigator: Jerry A. Nick
Current Award Period: 1/1/10-12/31/10
Total Award Period: 11/1/03-12/31/10
Current NJC subcontract: $86,000
Total Award Budget: $607,403
Specific Aim: Support for clinical trials
Multi-center Trial to Validate Protein Biomarkers of a Pulmonary Exacerbation in CF
CFF
Local Site PI: Jerry A. Nick
Award Period: 2/1/08-present
Current Budget: $45,000
Specific Aims:
- To develop a CF lung injury biomarker panel that quickly demonstrates a response to treatment by determining changes in candidate protein biomarkers in blood before and after intravenous antibiotic treatment for an acute pulmonary exacerbation.
- To determine whether these candidate protein biomarkers in blood also predict a subsequent decline in lung function by collecting these specimens at a time of clinical stability in the same cohort as specific aim #1 (“return to baseline” samples) and annually over two subsequent years.
- To submit high-quality plasma samples, collected under strict industry-accepted SOPs from a large cohort of well-characterized CF persons, to the CFFT Sample Bank which can be made available to other investigators interested in CF biomarker research.
Harry Schwachman Clinical Investigator Award
CFF
PI: R.L. Young, Sponsor: Jerry A. Nick
Award Period: 7/08-6/11
Current Budget: $100,000
Specific Aims: This three-year award provides the opportunity for clinically-trained physicians to develop into independent biomedical research investigators who are actively involved in CF-related areas.
Expanded Access Trial of Aztreonam for Inhalation
Gilead
Local Site PI: Jerry A. Nick
Award Period: 5/01/09-present
Current Budget: $10,000
Specific Aim: A Phase IV trial of inhaled aztreonam therapy in adults with Cystic Fibrosis.
Testing Redox Regulation as Anti-inflammatory Therapy in Cystic Fibrosis Lung Disease
KL2 Mentored Career Development Award (NIH)
PI: D.P. Nichols, Co-mentor: Jerry A. Nick
Award Period: 9/10-8/13
Current Budget: $140,000
Specific Aims: This three-year award provides the opportunity for early stage physician scientist to develop into independent biomedical research investigators.